08:34 AM EDT, 03/23/2026 (MT Newswires) -- Enlivex ( ENLV ) said Monday it obtained investigational new drug clearance from the US Food and Drug Administration to begin a phase 2b trial of Allocetra, a potential treatment for moderate-to-severe age-related symptomatic primary knee osteoarthritis.

The phase 2b trial will evaluate the efficacy and safety of intra-articular injections of the treatment, the company said.

The trial's key efficacy endpoints include the change from baseline in pain and physical function compared with placebo, measured at three and six months following treatment with the drug, Enlivex ( ENLV ) said.